Stockscreener 앱 받기
6.89
4.57%
-0.33
시간 외 거래:
6.81
-0.08
-1.16%
전일 마감가:
$7.22
열려 있는:
$7.25
하루 거래량:
24,707
Relative Volume:
0.76
시가총액:
$134.57M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-12.78%
1개월 성능:
-1.85%
6개월 성능:
-7.64%
1년 성능:
+0.00%
1일 변동 폭
$6.64
$7.25
1주일 범위
$6.10
$7.975
52주 변동 폭
$5.51
$11.73
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
ACTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
6.89 | 134.57M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | H.C. Wainwright | Buy |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Will Actuate's Elraglusib Prove To Be A Game Changer In The Fight Against Aggressive Cancers? - RTTNews
Soft Tissue Sarcoma with Lung Metastases Treatment Market Size - openPR.com
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight - Barchart.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - Marketscreener.com
Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC - MarketScreener
Growth Driver In The Locally Advanced Pancreatic Cancer Market 2 - News Channel Nebraska Southeast
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (NASDAQ:ACTU) - Seeking Alpha
Brokers Set Expectations for ACTU Q1 Earnings - Defense World
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR.com
WIN Consortium leading the future of precision cancer medicine - EurekAlert
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation - Nasdaq
Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer - TipRanks
Actuate Therapeutics Inc. (ACTU) reports earnings - Quartz
ACTUATE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Neuroblastoma Pipeline 2025: Key Companies, MOA, ROA, - openPR
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
Pancreatic And Bile Duct Cancer Drug Market Enhancing Cybersecurity and Cloud Integration for the Future - ExpressVartha
Actuate reports progress in pancreatic cancer trial By Investing.com - Investing.com Australia
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Actuate Announces Completion of Enrollment in a Phase 2 - GlobeNewswire
Actuate reports progress in pancreatic cancer trial - Investing.com India
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer - Yahoo Finance
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - Marketscreener.com
Adenoid Cystic Carcinoma Market: Analysis of Epidemiology, - openPR
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Pancreatic Adenocarcinoma Market Growth Projections - openPR
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth? - simplywall.st
Actuate Therapeutics sets annual meeting for May 22 - MSN
How To Work With Trump, The Future Of US Life Sciences And More: Updates From BIO CEO & Investor - Scrip
Actuate Therapeutics' IPO Lock-up Period Expires Today - RTTNews
Certain Restricted Stock Units of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Stock Options of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Common Stock of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Actuate Therapeutics, Inc. to Hold Annual Meeting of Stockholders on May 22, 2025 - Armenian Reporter
Invesco BulletShares 2019 Corporate Bond ETF (NYSEARCA:BSCJ) Stock Price Down 0% – Here’s Why - Armenian Reporter
Actuate Therapeutics sets annual meeting for May 22 By Investing.com - Investing.com UK
Matrix Service (NASDAQ:MTRX) Posts Earnings Results, Beats Expectations By $0.02 EPS - Armenian Reporter
Actuate Therapeutics' Lock-Up Period Will Expire on February 10th (NASDAQ:ACTU) - MarketBeat
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th - Defense World
Alterity surges after mid-stage trial data for lead asset - MSN
Actuate Therapeutics (NASDAQ:ACTU) Trading Down 5.4%Here's What Happened - MarketBeat
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):